Prognostic role of optical coherence tomography after switch to dexamethasone in diabetic macular edema

Abstract

Aims

To analyze the visual outcome after early switch to dexamethasone (DEX) in eyes with diabetic macular edema previously treated with ranibizumab (RNB), based on structural spectral-domain optical coherence tomography (SD-OCT) features.

Methods

Retrospective study of data from 28 eyes which underwent a loading dose of three monthly RNB injections and were then shifted to DEX implant injection. SD-OCT analysis was performed before switch to DEX (week 12, 12W) according to the presence of integrity of ellipsoid zone (EZ) and external limiting membrane (ELM), disorganization of retinal inner layers (DRIL), and quantity of hyper-reflective spots (HRS). Best-corrected visual acuity (BCVA) changes at different time points after DEX (month 1, 1M; 4 months, 4M; and 12 months, 12M) were compared among groups.

Results

Significantly better BCVA was achieved at 1M in eyes with intact EZ (84.2 ± 12.3 letters; p  =  0.04), with intact ELM (83.2 ± 11.5 letters; p < 0.01), and with fewer HRS (84.6 ± 12.5 letters; p = 0.03). However, the greatest percentage visual increase was achieved in eyes with disrupted EZ (+ 11.4%; p < 0.01), with disrupted ELM (+ 17.2%; p < 0.01), without DRIL (+ 12.5%; p < 0.01), and with more HRS (+ 14.3%; p = 0.04). After 12 months, a significant BCVA gain was observed only in eyes with intact retinal inner layers (+ 14.2%; p = 0.03).

Conclusions

Greater percentage BCVA improvement at 1M after switch to DEX was associated with EZ disruption, ELM disruption, intact retinal inner layers, and higher quantity of HRS. A switch to DEX therapy would be useful in patients with these SD-OCT features.

This is a preview of subscription content, access via your institution.

Fig. 1

References

  1. 1.

    The Eye Diseases Prevalence Research Group (2004) The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 122(4):552–563

    Article  Google Scholar 

  2. 2.

    Bandello F, Cicinelli MV, Battaglia Parodi M (2015) Intravitreal ranibizumab for diabetic macular edema. Eur Ophthalmic Rev 9:25–31

    Article  Google Scholar 

  3. 3.

    Iacono P, Battaglia Parodi M, Bandello F (2010) Anti-vascular endothelial growth factor in diabetic retinopathy. Dev Ophthalmol 46:39–53

    CAS  Article  Google Scholar 

  4. 4.

    Bandello F, Berchicci L, La Spina C, Battaglia Parodi M, Iacono P (2012) Evidence for anti-VEGF treatment of diabetic macular edema. Ophthalmic Res 48:16–20

    CAS  Article  Google Scholar 

  5. 5.

    Shah SU, Maturi RK (2017) Therapeutic options in refractory diabetic macular oedema. Drugs 77:481–492

    CAS  Article  Google Scholar 

  6. 6.

    Nurözler Tabakcı B, Ünlü N (2017) Corticosteroid treatment in diabetic macular edema. Turk J Ophthalmol 47:156–160

    Article  Google Scholar 

  7. 7.

    Vujosevic S, Torresin T, Bini S et al (2016) Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema. Acta Ophthalmol 95:464–471

    Article  Google Scholar 

  8. 8.

    Bandello F, Cunha-Vaz J, Chong NV et al (2012) New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel. Eye 26:485–493

    CAS  Article  Google Scholar 

  9. 9.

    Bandello F, Battaglia Parodi M, Tremolada G, Lattanzio R, De Benedetto U, Iacono P (2010) Steroids as part of combination treatment: the future for the management of macular edema? Ophthalmologica 224(1):41–45

    CAS  Article  Google Scholar 

  10. 10.

    Cicinelli MV, Cavalleri M, Querques L, Rabiolo A, Bandello F, Querques G (2017) Early response to ranibizumab predictive of functional outcome after dexamethasone for unresponsive diabetic macular oedema. Br J Ophthalmol 101:1689–1693

    Article  Google Scholar 

  11. 11.

    Fickweiler W, Schauwvlieghe AM, Schlingemann RO et al (2017) Predictive value of optical coherence tomographic features in the bevacizumab and ranibizumab in patients with diabetic macular edema (BRDME) study. Retina 38:812–819

    Article  Google Scholar 

  12. 12.

    Midena E, Bini S (2016) Multimodal retinal imaging of diabetic macular edema: toward new paradigms of pathophysiology. Graefes Arch Clin Exp Ophthalmol 254:1661–1668

    CAS  Article  Google Scholar 

  13. 13.

    Gonzalez VH, Campbell J, Holekamp NM et al (2016) Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I data. Am J Ophthalmol 177:230–231

    Google Scholar 

  14. 14.

    The Diabetic Retinopathy Clinical Research Network (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372(13):1193–1203

    Article  Google Scholar 

  15. 15.

    Maggio E, Sartore M, Attanasio M et al (2018) Anti-VEGF treatment for diabetic macular edema in a real-world clinical setting. Am J Ophthalmol 195:209–222

    CAS  Article  Google Scholar 

  16. 16.

    The Diabetic Retinopathy Clinical Research Network (2007) Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 114:525–536

    Article  Google Scholar 

  17. 17.

    Maheshwary AS, Oster SF, Yuson RM, Cheng L, Mojana F, Freeman WR (2010) The association between percent disruption of the photoreceptor inner segment-outer segment junction and visual acuity in diabetic macular edema. Am J Ophthalmol 150:63–67

    Article  Google Scholar 

  18. 18.

    Santos AR, Costa M, Schwartz C et al (2018) Optical coherence tomography baseline predictors for initial best-corrected visual acuity response to intravitreal anti-vascular endothelial growth factor treatment in eyes with diabetic macular edema: the CHARTRES study. Retina 38:1110–1119

    CAS  Article  Google Scholar 

  19. 19.

    Zur D, Iglicki M, Busch C et al (2018) OCT biomarkers as functional outcome predictors in diabetic macular edema treated with dexamethasone implant. Ophthalmology 125:267–275

    Article  Google Scholar 

  20. 20.

    Seo KH, Yu SY, Kim M, Kwak HW (2016) Visual and morphologic outcomes of intravitreal ranibizumab for diabetic macular edema based on optical coherence tomography patterns. Retina 36(3):588–595

    CAS  Article  Google Scholar 

  21. 21.

    Sonoda S, Sakamoto T, Yamashita T, Shirasawa M, Otsuka H, Sonoda Y (2014) Retinal morphologic changes and concentrations of cytokines in eyes with diabetic macular edema. Retina 34(4):741–748

    CAS  Article  Google Scholar 

  22. 22.

    Sun JK, Lin MM, Lammer J et al (2014) Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema. JAMA Ophthalmol 132:1309–1316

    Article  Google Scholar 

  23. 23.

    Vujosevic S, Bini S, Torresin T et al (2017) Hyperreflective retinal spots in normal and diabetic eyes: B-scan and en face spectral domain optical coherence tomography evaluation. Retina 37:1092–1103

    Article  Google Scholar 

  24. 24.

    Madeira MH, Boia R, Santos PF, Ambrósio AF, Santiago AR (2015) Contribution of microglia-mediated neuroinflammation to retinal degenerative diseases. Mediat Inflamm 2015:673090

    Article  Google Scholar 

  25. 25.

    Chatziralli I, Theodossiadis P, Parikakis E et al (2017) Dexamethasone intravitreal implant in diabetic macular edema: real-life data from a prospective study and predictive factors for visual outcome. Diabetes Ther 8:1393–1404

    CAS  Article  Google Scholar 

  26. 26.

    Hwang HS, Chae JB, Kim JY, Kim DY (2017) Association between hyperreflective dots on spectral-domain optical coherence tomography in macular edema and response to treatment. Investig Ophthalmol Vis Sci 58:5958–5967

    CAS  Article  Google Scholar 

  27. 27.

    Pilotto E, Bini S, Midena E (2018) Is diabetic retinopathy an inflammatory disease? Minerva Oftalmol 60:26–35

    Google Scholar 

Download references

Funding

The contribution by IRCCS Fondazione Bietti in this paper was financially supported by Italian Ministry of Health and Fondazione Roma. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author information

Affiliations

Authors

Contributions

All the authors contributed to the conception or design of the work, the acquisition, analysis and interpretation of data, drafting the work, revising it critically for important intellectual content and gave final approval of the version to be published.

Corresponding author

Correspondence to Giuseppe Querques.

Ethics declarations

Conflict of interest

Michele Cavalleri, Maria Vittoria Cicinelli, Riccardo Sacconi, Daniele De Geronimo: none. Francesco Bandello consultant for: Alcon (Fort Worth,Texas,USA), Alimera Sciences (Alpharetta, Georgia, USA), Allergan Inc (Irvine, California,USA), Farmila-Thea (Clermont-Ferrand, France), Bayer Shering-Pharma (Berlin, Germany), Bausch And Lomb (Rochester, New York, USA), Genentech (San Francisco, California, USA), Hoffmann-La-Roche (Basel, Switzerland), NovagaliPharma (Évry, France), Novartis (Basel, Switzerland), Sanofi-Aventis (Paris, France), Thrombogenics (Heverlee,Belgium), Zeiss (Dublin, USA). Giuseppe Querques consultant for: Alimera Sciences (Alpharetta, Georgia, USA), Allergan Inc (Irvine, California,USA), Heidelberg (Germany), Novartis (Basel, Switzerland), Bayer Shering-Pharma (Berlin, Germany), Zeiss (Dublin, USA). Mariacristina Parravano consultant for: Allergan Inc (Irvine, California, USA), Bayer Shering-Pharma (Berlin, Germany), Novartis (Basel, Switzerland). Monica Varano consultant for: Allergan Inc (Irvine, California, USA), Bayer Shering-Pharma (Berlin, Germany), Novartis (Basel, Switzerland).

Ethical approval

This study was conducted in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Managed by Massimo Federici.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cavalleri, M., Cicinelli, M.V., Parravano, M. et al. Prognostic role of optical coherence tomography after switch to dexamethasone in diabetic macular edema. Acta Diabetol 57, 163–171 (2020). https://doi.org/10.1007/s00592-019-01389-4

Download citation

Keywords

  • Diabetic macular edema
  • Anti-VEGF
  • Dexamethasone
  • Optical coherence tomography